Sanofi India Limited has received Central Government approval for the appointment of Mr. Deepak Arora as Managing Director, marking a significant milestone in the company's leadership transition. The pharmaceutical company informed the stock exchanges about this development on April 2, 2026.

Government Approval Details

The Ministry of Corporate Affairs granted approval for Mr. Deepak Arora's appointment through its letter dated April 1, 2026. The approval covers his tenure as Managing Director for a three-year period under the Companies Act, 2013.

Previous Intimations and Timeline

Sanofi India had previously informed the exchanges about Mr. Arora's appointment on two occasions - October 27, 2025 and December 18, 2025 - with the caveat that it was subject to Central Government approval. The company filed its application with the government on January 21, 2026, through SRN AC1430577.

Regulatory Conditions

The government approval comes with specific conditions that Mr. Arora must adhere to during his tenure:

• He must provide an undertaking that he will not become interested in any selling agency of the company without prior government approval
• This restriction extends to his wife and minor children
• His headquarters shall be fixed at the place where he regularly stays for attending duties
• The appointment remains conditional upon furnishing the required undertaking

Compliance and Notifications

Company Secretary and Compliance Officer Haresh Vala signed the notification to the exchanges, ensuring compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The approval letter was received via email on April 1, 2026, and promptly communicated to BSE and NSE the following day.

The government clarified that this approval is specific to the Companies Act, 2013 provisions and does not cover requirements under other laws or regulations. The appointment will be governed by relevant provisions of the Act regarding management powers and related matters.

Sanofi India Limited has published newspaper notices regarding its 70th Annual General Meeting and final dividend arrangements, following the Board of Directors meeting held on March 25, 2026. The pharmaceutical company has fulfilled regulatory requirements by publishing the AGM notice in Business Standard (English) and Sakal (Marathi) newspapers on March 31, 2026.

Annual General Meeting and Dividend Details

The company has confirmed the scheduling of its 70th Annual General Meeting with comprehensive arrangements for shareholder participation:

The final dividend of Rs. 48.00 per equity share of Rs. 10.00 each for the Financial Year ended December 31, 2025, was previously recommended by the Board on February 25, 2026, and remains subject to member approval at the upcoming AGM.

New Independent Director Appointment

Based on the Nomination and Remuneration Committee's recommendation, the Board has approved the appointment of Mr. Siraj Azmat Chaudhry as Additional Director and Independent Director:

Special Window for Share Transfers

SEBI has opened a special window for transfer and dematerialization of physical securities through Circular No. HO/38/13/11(2)/2026-MIRSD-POD/I/3750/2026 dated January 30, 2026. This facility is available for securities sold/purchased before April 1, 2019:

Regulatory Compliance and Publication

The newspaper publication was made in compliance with SEBI regulations and MCA circulars regarding AGM conduct through video conferencing. The announcement includes comprehensive details about:

• KYC registration requirements for shareholders
• E-voting procedures for remote and AGM participation
• Tax deduction at source on dividend payments
• Bank account detail updates for dividend processing

The company has ensured all regulatory disclosures are made in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, maintaining transparency and stakeholder engagement throughout the process.